Simon Hsu1, Nisha Bansal. 1. Department of Medicine/Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: Heart failure is highly prevalent in patients with chronic kidney disease (CKD) and a leading cause of morbidity and mortality in this population. Heart failure therapies proven to benefit the general population may have different risk-benefit profiles in patients with concurrent CKD, plausibly because of the unique pathophysiology of heart failure in this population. The present review highlights recent advances in heart failure treatment as they apply to patients with CKD. RECENT FINDINGS: Several recent publications have shown possible benefits of established heart failure therapies to improve clinical outcomes in patients with CKD; while others conclude neutral or even harmful effects of heart failure therapies in CKD patients. Novel heart failure therapies show promise to improve outcomes in the general population and should be evaluated in future studies to further elucidate the efficacy and safety of these novel therapies specifically in patients with CKD. SUMMARY: Knowledge of heart failure treatment to improve clinical outcomes in the CKD population remains limited. Future studies should focus on patients with CKD to evaluate the generalizability of heart failure therapies to this patient population.
PURPOSE OF REVIEW: Heart failure is highly prevalent in patients with chronic kidney disease (CKD) and a leading cause of morbidity and mortality in this population. Heart failure therapies proven to benefit the general population may have different risk-benefit profiles in patients with concurrent CKD, plausibly because of the unique pathophysiology of heart failure in this population. The present review highlights recent advances in heart failure treatment as they apply to patients with CKD. RECENT FINDINGS: Several recent publications have shown possible benefits of established heart failure therapies to improve clinical outcomes in patients with CKD; while others conclude neutral or even harmful effects of heart failure therapies in CKDpatients. Novel heart failure therapies show promise to improve outcomes in the general population and should be evaluated in future studies to further elucidate the efficacy and safety of these novel therapies specifically in patients with CKD. SUMMARY: Knowledge of heart failure treatment to improve clinical outcomes in the CKD population remains limited. Future studies should focus on patients with CKD to evaluate the generalizability of heart failure therapies to this patient population.
Authors: Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Nisha Bansal; Ronit Katz; Cassianne Robinson-Cohen; Michelle C Odden; Lorien Dalrymple; Michael G Shlipak; Mark J Sarnak; David S Siscovick; Leila Zelnick; Bruce M Psaty; Bryan Kestenbaum; Adolfo Correa; Maryam Afkarian; Bessie Young; Ian H de Boer Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Sharon M Moe; Glenn M Chertow; Patrick S Parfrey; Yumi Kubo; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; David C Wheeler; Maria Stolina; Bastian Dehmel; William G Goodman; Jürgen Floege Journal: Circulation Date: 2015-06-09 Impact factor: 29.690
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Richard Haynes; Parminder K Judge; Natalie Staplin; William G Herrington; Benjamin C Storey; Angelyn Bethel; Louise Bowman; Nigel Brunskill; Paul Cockwell; Michael Hill; Philip A Kalra; John J V McMurray; Maarten Taal; David C Wheeler; Martin J Landray; Colin Baigent Journal: Circulation Date: 2018-10-09 Impact factor: 29.690
Authors: Bertram Pitt; David A Bushinsky; Dalane W Kitzman; Frank Ruschitzka; Marco Metra; Gerasimos Filippatos; Patrick Rossignol; Charles Du Mond; Dahlia Garza; Lance Berman; Mitja Lainscak Journal: ESC Heart Fail Date: 2018-01-25
Authors: Gerasimos Filippatos; Stefan D Anker; Michael Böhm; Mihai Gheorghiade; Lars Køber; Henry Krum; Aldo P Maggioni; Piotr Ponikowski; Adriaan A Voors; Faiez Zannad; So-Young Kim; Christina Nowack; Giovanni Palombo; Peter Kolkhof; Nina Kimmeskamp-Kirschbaum; Alexander Pieper; Bertram Pitt Journal: Eur Heart J Date: 2016-04-29 Impact factor: 35.855
Authors: Gwen M Bernacki; Cara L McDermott; Daniel D Matlock; Ann M O'Hare; Lyndia Brumback; Nisha Bansal; James N Kirkpatrick; Ruth A Engelberg; Jared Randall Curtis Journal: J Pain Symptom Manage Date: 2021-08-04 Impact factor: 3.612